Search results
Appeals court does not block US mandate to cover cancer screenings, HIV drugs
Reuters via AOL· 16 minutes agoA U.S. appeals court on Friday refused to block a federal mandate requiring health insurers to cover...
AstraZeneca's breast cancer drug combination fails in late-stage trial
Reuters via AOL· 4 days agoTriple-negative breast cancer remains one of the most challenging forms of disease to treat due to...
Therapist Dying of Cancer Leaves Viral Goodbye Message: 'I Was Completely Shocked,' Husband Says...
People Magazine· 2 days agoOn June 1, New York City psychologist and author Sarah Mandel posted a video on social media that...
BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay
Bloomberg· 4 days agoThe Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental...
What to do if breast cancer recurs
Rolling Out· 5 days agoBreast cancer recurrence is a challenging and frightening experience for many survivors. After going through the initial treatment and feeling the relief...
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
Reuters via AOL· 4 days agoThe drug, an antibody-drug conjugate (ADC), was being studied in a trial sponsored by China-based...
Combination therapy shows promise in subset of breast cancers
Medical Xpress· 4 days agoCombining two cancer drugs may be a promising treatment for advanced metastatic breast cancer,...
Researchers discover promising approach to prevent recurrence of breast cancer
Medical Xpress· 4 days agoAlthough treatment outcomes for breast cancer have significantly improved through new research-based therapies, it remains the second most common fatal ...
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
Zacks via Yahoo Finance· 1 day agoThe European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 3 days agoThe study did not meet the dual primary endpoints of improvement in overall survival (OS) versus...